drugset / Trial / NCT01893151

Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI

NCT01893151

Phase 4 Unknown 200 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of Iguratimod versus placebo on synovial inflammation,bone erosion and bone edema as measured by MRI of wrist and Metacarpophalangeal joints in patients with early Rheumatoid Arthritis (RA).

Timeline

Start
2012-07
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Iguratimod Small molecule 25 mg Oral

Indications